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Introduction
Eukaryotic cells contain very extensive intracellular
membrane systems, and many vital cellular processes,
such as metabolic reactions, signal transduction, cyto-
skeletal rearrangements, protein sorting and regulation
of membrane dynamics, occur partially or entirely at
membrane–cytosol interfaces. The main advantages of
executing biochemical reactions on membranes include
the limitation of substrate diffusion (i.e. limited to two
dimensions instead of three) and the possibility of con-
ﬁning biochemical processes to restricted subcellular
locations.
The containment of cellular processes to intra-
cellular membranes requires the reversible assembly of
protein complexes onto speciﬁc membranes. A group
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Phosphorylated derivatives of the membrane lipid phosphatidylinositol
(PtdIns), known as phosphoinositides (PIs), regulate membrane-proximal
cellular processes by recruiting speciﬁc protein effectors involved in cell
signalling, membrane trafﬁcking and cytoskeletal dynamics. Two PIs that
are generated through the activities of distinct PI 3-kinases (PI3Ks) are of
special interest in cancer research. PtdIns(3,4,5)P3, generated by class I
PI3Ks, functions as tumour promotor by recruiting effectors involved in
cell survival, proliferation, growth and motility. Conversely, there is
evidence that PtdIns3P, generated by class III PI3K, functions in tumour
suppression. Three subunits of the class III PI3K complex (Beclin 1, UVRAG
and BIF-1) have been independently identiﬁed as tumour suppressors in
mice and humans, and their mechanism of action in this context has been
proposed to entail activation of autophagy, a catabolic pathway that is
considered to mediate tumour suppression by scavenging damaged organ-
elles that would otherwise cause DNA instability through the production
of reactive oxygen species. Recent studies have revealed two additional
functions of PtdIns3P that might contribute to its tumour suppressor activ-
ity. The ﬁrst involves endosomal sorting and lysosomal downregulation of
mitogenic receptors. The second involves regulation of cytokinesis, which is
the ﬁnal stage of cell division. Further elucidation of the mechanisms of
tumour suppression mediated by class III PI3K and PtdIns3P will identify
novel Achilles’ heels of the cell’s defence against tumourigenesis and will be
useful in the search for prognostic and diagnostic biomarkers in cancer.
Abbreviations
EEA1, early endosomal autoantigen 1; ER, endoplasmic reticulum; ESCRT, endosomal sorting complex required for transport;
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FEBS Journal 277 (2010) 4837–4848 ª 2010 The Author Journal compilation ª 2010 FEBS 4837of phosphorylated derivatives of phosphatidylinositol
(PtdIns), collectively known as phosphoinositides (PIs),
are ideally suited for this task [1]. The PIs are gener-
ated and metabolized through the activities of a num-
ber of substrate-speciﬁc PI kinases and phosphatases,
the dysfunctions of which are associated with various
human diseases [2]. Of special interest in cancer
research are two PI 3-kinases (i.e. kinases that phos-
phorylate the inositol headgroup in the 3-position) that
have opposing roles in tumourigenesis. Class I PI
3-kinase (PI3K-I), on the one hand, is a well-known
tumour promoting enzyme (or to be more precise, a
small group of related enzymes) whose hyperactivity is
strongly associated with carcinogenesis in humans [3].
Consistent with this, PTEN, a phosphatase that essen-
tially reverses the 3-phosphorylation mediated by
PI3K-I, is an important tumour suppressor [4]. The
catalytic product of PI3K-I, PtdIns(3,4,5)P3, recruits
several proteins involved in cell signalling to the
plasma membrane, the most important one being the
protein kinase AKT, which orchestrates various signal-
ling cascades that promote cell growth and survival.
On the other hand, class III PI 3-kinase (PI3K-III) is
considered to be a tumour suppressor based on the
ﬁndings that three of its accessory subunits, Beclin 1,
UVRAG and BIF-1, have been independently identi-
ﬁed as tumour suppressors whose partial or complete
inactivation causes the increased occurrence of sponta-
neous tumours in mice and (probably) humans [5–7].
Recently identiﬁed molecular and cellular mechanisms
that may serve to explain the tumour suppressor func-
tions of PI3K-III are the topic of the present review.
PI3K-III: a conserved lipid kinase
complex
The catalytic subunit of PI3K-III was ﬁrst identiﬁed as
Vps34, an enzyme that mediates vacuolar protein sort-
ing in the yeast Saccharomyces cerevisiae [8]. By con-
trast to PI3K-I, PI3K-III is conserved between yeast,
plants and humans, and the human homologue of
Vps34 is referred to as hVps34, PIK3C3 or VPS34. In
the present review, the latter term is used. Subsequent
work soon revealed that Vps34 is associated with a
regulatory subunit, Vps15, a putative protein kinase
[9]. More recently, Vps34 was found to engage in two
functionally distinct complexes in yeast. One complex,
consisting of Vps34, Vps15, Vps30 and Vps38, regu-
lates endosomal sorting, whereas another complex, in
which Vps38 is replaced by Atg14, is required for
autophagy [10].
The two PI3K-III complexes in yeast have their
human counterparts: one consisting of VPS34, VPS15,
the Vps30 homologue Beclin 1 and the Vps38 homo-
logue UVRAG, and the other containing ATG14 (also
called hAtg14, Atg14L or Barkor) instead of UVRAG
[11–14]. Thus, we can consider VPS34-VPS15-Beclin 1
as a core complex onto which the accessory subunits
UVRAG and ATG14 can assemble in a competitive
manner (Fig. 1A). In addition, the UVRAG containing
complex can associate with Rubicon, a protein that
negatively regulates the function of this complex in
endosomal and autophagic trafﬁcking [11,12], and with
BIF-1 (also known as endophilin B1 or SH3GLB1),
identiﬁed as a positive regulator of autophagy [5]
(Fig. 1B). Although Rubicon can be isolated as a
major constituent of UVRAG-containing PI3K-III
complexes, this is not the case with BIF-1, which
appears to be more transiently associated [12,15]. Nev-
ertheless, the fact that BIF-1 contains an amino-termi-
nal BAR domain predicted to have membrane-bending
ability, as well as the ﬁnding that knockdown of BIF-1
inhibits the catalytic activity of PI3K-III, suggests that
this protein is an important accessory subunit of mam-
malian PI3K-III [5]. BAR domain proteins have been
found to associate with membranes of high curvature
[16], and it is tempting to speculate that BIF-1 might
direct PI3K-III activity to such membranes.
The recently solved crystal structure of Drosophila
melanogaster Vps34 revealed that this PI3K has a
considerably smaller ATP-binding pocket than class I
PI3Ks [17]. This explains why several inhibitors of
class I PI3Ks fail to inhibit class III PI3K (i.e. they are
too bulky to ﬁt into the ATP-binding pocket). More
importantly, the structural insight offers a rationale
for designing speciﬁc PI3K-III inhibitors in the future.
Even though considerable knowledge has been
gained about the biochemical composition of PI3K-III,
we still know little about the regulation of its catalytic
activity. The catalytic activity appears to be stimulated
by BIF-1, whereas Rubicon inhibits the overall func-
tion of PI3K-III [5,11,12]. However, the exact mecha-
nisms of these regulations remain unsolved. An
important clue to the regulation of VPS34 has emerged
recently with the ﬁnding that VPS34 is phosphorylated
on threonine 159 by the cyclin-dependent kinase Ckd1
during mitosis, and that this causes its dissociation
from Beclin 1 and an inhibition of autophagy [18].
Recognition of PtdIns3P by FYVE and
phox homology (PX) domains
A breakthrough in our understanding of how PI3K-III
and its catalytic product control cellular functions
came with the identiﬁcation of the FYVE (conserved
in Fab1, YOTB, Vac1 and EEA1) domain, and the
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FYVE domain was originally identiﬁed as a zinc ﬁnger
required for localization of the early endosomal autoan-
tigen 1 (EEA1) to early endosomes [19]. The ﬁnding
that wortmannin, a general PI3K inhibitor, prevents
the localization of EEA1 to endosomes, provided a clue
that EEA1 might be recruited by a 3-phosphorylated PI
[20], and biochemical studies showed that the FYVE
domains from yeast and mammalian proteins bind to
PtdIns3P with high speciﬁcity [21–23]. Further progress
in deciphering the downstream functions of PtdIns3P
was obtained when the PX domain was identiﬁed as a
second PtdIns3P binding domain [24–27]. Although a
few mammalian PX domains bind to other 3-PIs than
PtdIns3P, most of the PX domains bind speciﬁcally to
PtdIns3P with afﬁnities comparable to those of FYVE
domains [28]. The human genome encodes approxi-
mately 30 FYVE domain-containing proteins and some
45 PX domain-containing proteins that presumably
mediate most (but not all) of the downstream functions
of PtdIns3P [29]. Additional PtdIns3P-binding proteins
that do not contain FYVE or PX domains include the
Proppin⁄WIPI proteins, which bind PtdIns3P [and to
some extent the related PtdIns(3,5)P2] through a
WD40-repeat-containing b-propeller structure [30,31],
and certain variant pleckstrin homology domains such
as the GLUE (GRAM-like ubiquitin-binding in
EAP45) domain [32–34].
Intracellular localization of PtdIns3P
The identiﬁcation of PtdIns3P-binding domains
offered the possibility to design probes that reveal the
intracellular distribution of this lipid. Early work
revealed that a single FYVE domain from the endoso-
mal protein HRS binds PtdIns3P with too low afﬁnity
to be useful as a probe. Remarkably, however, when
two FYVE domains from HRS were fused in tandem
(2xFYVE), the resulting construct could be used for
imaging of cellular PtdIns3P with high sensitivity and
speciﬁcity, presumably as a result of an avidity effect
[35]. The fact that 2xFYVE can be either transfected
into cells as a fusion with green ﬂuorescent protein or
another tag, or expressed in bacteria and puriﬁed as a
Fig. 1. The human PI3K-III complex. (A) The
various subunits of PI3K-III are indicated.
VPS34, VPS15 and Beclin 1 are considered
to form a core complex onto which acces-
sory subunits can assemble. HEAT repeats
(H), WD40 repeats (WD), Bcl-2 binding
domain (BD), zinc ﬁngers (ZF) and coiled-coil
domains (CC) are indicated. Note that there
exist alternative sequence variants for most
of the subunits (not indicated). (B) Distinct
PI3K-III subcomplexes regulate autophago-
some formation and endosomal trafﬁc.
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specimens, makes this probe very versatile for monitor-
ing the distribution of PtdIns3P. Subsequently, other
probes have been used for monitoring PtdIns3P,
including the FYVE domain of SARA, which has an
intrinsic ability to dimerize and therefore does not
need to be expressed as tandem fusion [36], and certain
PX domains [37]. In general, the various probes have
yielded comparable results, although the 2xFYVE
probe has been most rigorously tested for ligand speci-
ﬁcity. The original studies using 2xFYVE by ﬂuores-
cence and electron microscopy showed that the bulk of
PtdIns3P is associated with the limiting and intralumi-
nal membranes of endosomes at steady-state [35]. Sub-
sequent studies have revealed that PtdIns3P can also
be detected at the plasma membrane of cells stimulated
with insulin or lysophosphatidic acid [38,39]. Because
this pool of PtdIns3P is generated through the activity
of PI3K-II [40], which has so far not been implicated
in tumour suppression, it will not be considered further
in the present review. Recent analyses of starved yeast
cells have revealed a strong localization of PtdIns3P
on autophagosomes, especially on the inner mem-
branes [41], and, during induction of autophagy in
mammalian cells, PtdIns3P is formed on membranes
of the endoplasmic reticulum (ER) [42]. The impor-
tance of this is discussed below.
PI3K-III and PtdIns3P binding proteins
in endosomal trafﬁcking
Because Vps34 and Vps15 were originally identiﬁed as
mediators of vacular protein sorting in yeast, the ﬁrst
characterized functions of PI3K-III and PtdIns3P were
those associated with endosomal trafﬁcking (Fig. 2A).
PtdIns3P and endosomal fusion
Yeast cells devoid of functional Vps34 or Vps15
secrete several hydrolases that normally are trans-
ported to the lysosome-like vacuole [8,43], suggesting
that these proteins control trafﬁcking between the
Fig. 2. PtdIns3P effectors in cell regulation. Endocytic downregulation of a mitogenic receptor (A), autophagy (B) and cytokinesis (C).
PtdIns3P effectors involved in the various processes are shown in red. Rabenosyn-5 and EEA1 mediate membrane fusion in the early endo-
cytic pathway. HRS and EAP45 are subunits of the ESCRT machinery that sorts ubiquitinated mitogenic receptors into the ILVs of multive-
sicular endosomes. DFCP1 mediates phagophore biogenesis, whereas WIPI2 mediates autophagosome biogenesis. FYVE-CENT facilitates
cytokinesis. Microtubules are indicated by dashed green lines.
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endosomes. A key effector of PtdIns3P in endocytic
trafﬁcking is the FYVE-domain-containing protein
Vac1, which interacts genetically and physically with
the small GTPase Vps21, and with Vps45, a member
of the Sec1⁄Munc18 family of proteins regulating the
formation of SNARE complexes that mediate mem-
brane fusion [44,45]. Indeed, studies of the mammalian
homologues of Vac1, Vps21 and Vps45, termed Rabe-
nosyn-5, RAB5 and VPS45, respectively, have revealed
that these proteins function in tethering and fusion
reactions in the early endocytic pathway [46]. More-
over, studies in Drosophila have revealed that Rabeno-
syn functions to bridge Rab5 with Vps45, thereby
regulating the function of the SNARE protein Ava-
lanche in endosomal fusion [47]. Interestingly, func-
tional interference with Rabenosyn-5 and its
interacting partners causes a loss of both epithelial and
planar polarity [47,48]. The loss of epithelial polarity is
a prevailing characteristic of carcinomas, and muta-
tion of Rabenosyn indeed causes epithelial tumours in
Drosophila. To date, the mechanisms by which Rabe-
nosyn controls epithelial polarity have not been eluci-
dated, whereas more detailed insight is available in the
case of planar cell polarity. One consequence of inter-
ferring with Rabenosyn function is that Flamingo, a
determinant of planar cell polarity through the nonca-
nonical Wnt signalling pathway, accumulates in the
cytoplasm instead of translocating to polarized mem-
brane domains [48]. Accumulating evidence suggests a
link between improper development of planar cell
polarity and cancer [49], and even though it is still not
clear whether Rabenosyn-5 is a tumour suppressor in
mammals, the epithelial and planar cell polarity main-
tained by this RAB5 and PtdIns3P effector has to be
considered when dissecting the tumour suppressor
activities of PI3K-III.
Early studies in mammalian cells have also revealed
another important PtdIns3P effector in endosomal
tethering and fusion, namely EEA1, a protein that
contains a Rab5 binding domain and a FYVE domain
at its C-terminus, and a distinct Rab5 binding domain
at its N-terminus [50]. EEA1 forms rod-shaped dimers
through parallel coiled-coil interactions, and is well
suited for tethering two opposing Rab5-containing
membranes [51]. The exquisite localization of EEA1 to
early endosomes is probably conferred by the coinci-
dent detection of PtdIns3P and GTP-bound Rab5 [50].
EEA1 is structurally related to Rabenosyn-5, and also
interacts with SNARE molecules [52,53]. In a remark-
able reconstitution of Rab5-mediated fusion using lipo-
somes and recombinant SNAREs and Rab5 effectors,
the inclusion of PtdIns3P could bypass the requirement
for PI3K-III, as expected based on previous studies [54].
Importantly, the omission of either EEA1 or Rabeno-
syn-5 was sufﬁcient to inhibit fusion strongly, indicating
that these proteins, despite their structural relatedness,
have nonredundant functions in endocytic membrane
fusion.
PtdIns3P and endosomal sorting to the
degradative pathway
Consistent with the fact that Vps34 was originally
identiﬁed as a mediator of protein sorting, studies of
both yeast and mammalian cells have shown that
PI3K-III is required for proper sorting of certain mem-
brane proteins from endosomes to vacuoles⁄lysosomes
[8,55]. Moreover, interference with the function of
VPS34 in mammalian cells results in dilated late endo-
somes devoid of intraluminal vesicles (ILVs) [56,57].
Recent studies have revealed that not only VPS34, but
also VPS15, Beclin 1, UVRAG and BIF-1 are required
for proper degradation of endocytosed epidermal
growth factor receptors in lysosomes, highlighting
the involvement of an entire PI3K-III complex in
endosomal sorting [15].
A mechanistic explanation for these ﬁndings has
emerged with the discovery of the endosomal sorting
complex required for transport (ESCRT) machinery
[58,59]. This molecular machinery, which consists of at
least four subcomplexes (ESCRT-0, -I, -II and -III), is
recruited to endosome membranes where it recognizes
ubiquitinated membrane proteins (e.g. activated
growth factor receptors and membrane-anchored
hydrolases) and sorts these into ILVs. Recent reconsti-
tution studies employing giant unilamellar vesicles
have revealed that ESCRT-0, which contains as many
as ﬁve ubiquitin-binding domains, serves to sequester
ubiquitinated cargoes, whereas ESCRT-I and -II,
which also contain ubiquitin-binding domains, serve to
form invaginations of the endosomal membrane [60].
Finally, ESCRT-III is recruited, cargo is deubiquitinat-
ed by deubiquitinating enzymes recruited by ESCRT-III
[61], and ESCRT-III serves to sever the neck of the
forming invagination, thereby securing the inclusion of
cargo proteins within ILVs [60]. The main link between
PI3K-III and the ESCRT pathway is the fact that
Vps27⁄HRS, a core component of ESCRT-0, contains
a FYVE domain that mediates its recruitment to
endosomal membranes through binding PtdIns3P [62].
Vps27⁄HRS in turn recruits ESCRT-I through interac-
tion with the Vps23⁄TSG101 subunit, so the initial
recruitment of ESCRT-0 to endosomal membranes via
FYVE-PtdIns3P interactions is crucial for the function
of the ESCRT machinery. In addition, a subunit of
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GLUE domain that is predicted to contribute to
the membrane recruitment of ESCRT-II [32,34]. The
involvement of the ESCRT machinery in protein sort-
ing and ILV biogenesis, as well as the notion that key
subunits of this machinery require PtdIns3P for their
membrane recruitment, readily explains why interfer-
ence with PI3K-III functions results in impaired
protein sorting and causes endosomes devoid of ILVs.
PI3K-III and PtdIns3P binding proteins
in autophagy
Macroautophagy (referred to here as autophagy) is a
process that involves the sequestration of cytoplasm by
a double membrane called phagophore or isolation
membrane, followed by fusion of the resulting auto-
phagosome with endosomes and lysosomes [63]
(Fig. 2B). The degradation of the sequestered cytosolic
material in autolysosomes is beneﬁcial for the cell,
both under starvation conditions (when it is crucial to
recycle free amino acids by degrading cytosolic pro-
teins that are not housekeeping), during infection with
cytosolic parasites, and under various stress conditions
(e.g. those that result in the accumulation of cytosolic
protein aggregates that are not readily degraded by
proteasomes). The exact origin of the phagophore
membrane is still a matter of debate, although there
are strong arguments in favour of a contribution from
both ER and mitochondrial membranes [42,64,65]. At
least in the case of ER membranes, there is evidence
for the production of PtdIns3P during the early phase
of autophagosome formation [42,66]. Several lines of
evidence point to a crucial role for PI3K-III in auto-
phagy [66], and immunoelectron microscopy of starved
yeast cells using the 2xFYVE probe has revealed that
PtdIns3P is enriched on inner side of the phagophore
during autophagosome formation [41].
Studies in yeast have revealed that a complex con-
sisting of Vps34, Vps15, Vps30 and Atg14 is required
for autophagy [10], and subsequent work in mamma-
lian cells has shown a similar requirement for the
mammalian homologues of these proteins [11,12].
In addition, an involvement of the Vps38 homologue
UVRAG has been reported [7], which is surprising in
light of the strong evidence that Vps38 mediates
endosomal trafﬁcking and not autophagy in yeast. A
possible role of UVRAG in autophagy is supported by
the independent identiﬁcation of BIF-1, an interactor
of UVRAG, as a regulator of autophagy [5]. On the
other hand, monoallelic UVRAG mutations associated
with microsatellite unstable colon cancer have no effect
on autophagy, and the depletion of UVRAG has an
undetectable effect on autophagy in HEK293 cells,
whereas endosomal sorting is affected [67]. One expla-
nation for the conﬂicting ﬁndings on UVRAG may
stem from the involvement of UVRAG in fusion
between autophagosomes (and late endosomes) and
lysosomes through its interactions with the HOPS
complex [68]. Except for the catalytic activity of
VPS34, little is known about the speciﬁc functions of
the various PI3K-III subunits in autophagy. However,
recent evidence suggests that the speciﬁc function of
ATG14 in autophagy may reﬂect the ability of this
protein to target PI3K-III to ER membranes [69].
How does PtdIns3P mediate autophagy? The only
known PtdIns3P effector in autophagy in yeast is the
Proppin protein Atg18 [70], whose binding to PtdIns3P
is required for autophagy [71]. Although the exact
function of Atg18 in autophagy remains to be clariﬁed,
current evidence suggests that this protein, in complex
with Atg2, facilitates the recruitment of lipidated Atg8,
a key effector in autophagosome formation to phago-
phore membranes [71]. A mammalian Atg18 homo-
logue, WIPI2, is recruited to phagophore membranes
along with ULK1, a protein kinase that positively reg-
ulates autophagy [72]. Interestingly, the depletion of
WIPI2 leads to a strong accumulation of omegasomes,
comprising ER-localized PtdIns3P-containing struc-
tures positive for DFCP1 (double FYVE domain-con-
taining protein 1) that are considered to act as
platforms for autophagosome formation. This suggests
a role for WIPI2 in the progression from omegasomes
into autophagosomes.
PI3K-III and PtdIns3P binding proteins
in cytokinesis
A surprising ﬁnding when using a green ﬂuorescent
protein-tagged version of the 2xFYVE probe was that
PtdIns3P accumulates in the bridge separating two
dividing cells, the so-called midbody. PtdIns3P is fre-
quently associated with the central, electron-dense part
of the midbody, referred to as the midbody ring or the
Flemming body, but can also be observed on small
vesicles throughout the midbody region [73]. This
localization of PtdIns3P raises the question of whether
its formation is required during cytokinesis, the ﬁnal
stage of cell division (Fig. 2C). Indeed, small interfer-
ing RNA-mediated knockdown of VPS34, as well as
of the accessory PI3K-III components VPS15, Beclin
1, UVRAG and BIF-1, causes an increased proportion
of cells undergoing cytokinesis, suggesting a role for
PI3K-III in the completion of cytokinesis [15,73].
Small interfering RNA screening identiﬁed the large
FYVE domain-containing protein FYVE-CENT
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in cytokinesis. FYVE-CENT localizes to the centro-
some in interphase cells and translocates to the mid-
body during telophase. This translocation appears to
be mediated by the microtubule-based motor protein
KIF13A. The precise function of FYVE-CENT during
cytokinesis remains to be characterized, although one
clue arises from the ﬁnding that TTC19, a protein that
associates with FYVE-CENT and accompanies it on
its translocation from the centrosome to the midbody,
interacts with the ESCRT-III subunit CHMP4B [73].
This is interesting because ESCRT-III has been pro-
posed to mediate the ﬁnal membrane abscission step
during cytokinesis [74,75], and it is possible that
TTC19, brought to the midbody by FYVE-CENT and
KIF13A, may be a positive regulator of CHMP4B in
cytokinesis. By analogy with its yeast counterpart
Vps32⁄Snf7, CHMP4B is predicted to form spiral-
shaped oligomers that constrict to mediate membrane
severing [76], and TTC19 might serve to control this
oligomerization.
PI3K-III and PtdIns3P effectors in
tumour suppression
The PI3K-III subunit Beclin 1 is monoallelically
deleted in a large proportion of breast and ovarian
cancers, and heterozygous beclin 1 knockout mice
develop spontaneous mammary tumours [6]. These
ﬁndings, combined with the observation that both
Beclin 1 and its yeast homologue Vps30 mediate auto-
phagy, suggest that Beclin 1 acts as a tumour suppres-
sor because of its function in autophagy. In support of
this idea, there is evidence that autophagy functions as
tumour suppressor by scavenging damaged mitochon-
dria and peroxisomes that would otherwise cause geno-
mic instability through oxygen radical-induced DNA
damage [77]. Further supporting the notion that PI3K-III
acts as a tumour suppressor through its function in
autophagy is the observation that two other PI3K-III
accessory proteins identiﬁed as positive regulators of
autophagy, UVRAG and BIF-1, are also tumour sup-
pressors [5,7]. Even though these are compelling data,
one obvious question arises regarding the role of
PI3K-III in autophagy-mediated tumour suppression:
are other autophagy regulators also tumour suppres-
sors? One would expect that this would be the case
but, so far, only one of the many other proteins impli-
cated in autophagy regulation has been identiﬁed as a
putative tumour suppressor, the protease ATG4C [78].
Because, among the more than 30 positive regulators
of autophagy, three out of four identiﬁed tumour
suppressors belong to the PI3K-III complex, the
possibility exists that PI3K-III may mediate tumour
suppression not by autophagy but by an alternative
means.
Given the importance of endocytosis and lysosomal
downregulation of growth factor receptors in attenua-
tion of mitogenic cell signalling [79], one distinct possi-
bility is that PI3K-III could (at least in part) exert its
tumour suppressor function through its role in endo-
some fusion and endosomal receptor sorting. Although
there is no direct evidence that this is the case, it is
interesting to note that the PtdIns3P-binding endoso-
mal fusion regulator, Rabenosyn, is a tumour suppres-
sor in ﬂies [47], and the same is the case with multiple
components of the ESCRT machinery that acts down-
stream of PtdIns3P in the endosomal sorting of mito-
genic receptors [80–83]. Arguing against this idea is the
fact that Hrs, the PtdIns3P binding ESCRT-0 protein
that initiates further ESCRT recruitment to mem-
branes, is not a tumour suppressor in Drosophila.
The recent discovery that PI3K-III regulates cytoki-
nesis has offered a third possible explanation for the
tumour suppressor activity of this enzyme complex
[73]. Inhibition of PI3K-III activity not only causes an
increased proportion of cells undergoing cytokinesis,
but also an increase in bi- and multinucleate cells.
Under certain conditions, tetraploidy may develop into
aneuploidy, which is strongly associated with cancer. It
is therefore likely that incomplete cytokinesis, as expe-
rienced when PI3K-III or the PtdIns3P effector
FYVE-CENT is functionally ablated, may represent a
step in oncogenesis [84]. It is interesting to note that
FYVE-CENT is frequently mutated in breast cancer
[85,86], although it remains to be established whether
this PtdIns3P effector is a genuine tumour suppressor.
Conclusions and perspectives
As discussed in the present review, PI3K-III may theo-
retically function as a tumour suppressor via at least
three different mechanisms (Fig. 3). The involvement
of PI3K-III in autophagy maintains genome stability
by eliminating damaged organelles that produce reac-
tive oxygen species; the role of PI3K-III in endo-
somal fusion and sorting ensures correct downregulation
of mitogenic signalling; and the correct function of
PI3K-III in cytokinesis prevents aneuploidy. Further
work is required to establish which of these three
processes is most important in PI3K-III-mediated
tumour suppression. It can also not be excluded that
PI3K-III may act as tumour suppressor by additional
means. For example, SARA, a mediator of transform-
ing growth factor-b signalling, requires PtdIns3P
binding for its function [87], and the transforming
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tumour suppressor role under most conditions [88].
Furthermore, PtdIns3P binding subunits mediate mem-
brane association of the retromer complex [89], which
sorts cargoes such as mannose 6-phosphate receptors
and Wntless (an accessory factor in Wnt secretion) for
trafﬁcking from endosomes to the biosynthetic path-
way [89,90]. Even though there is no evidence so far
that implicates the retromer in tumour suppression,
this possibility cannot at present be discarded.
The involvement of PI3K-III in diverse cellular pro-
cesses raises the question of how this complex is
recruited to the correct membranes at the right time.
There is evidence that PI3K-III is recruited to early
and late endosomal membranes through interactions
with the small GTPases RAB5 and RAB7, respectively
[91–93]. Less is known about how PI3K-III is recruited
to midbodies and autophagic membranes, although the
latter is likely to be mediated by the autophagy-speciﬁc
subunit ATG14 [69]. In addition, the ﬁnding that
phosphorylation of VPS34 during mitosis causes its
dissociation from Beclin 1 [18] provides a hint that
post-translational modiﬁcations of PI3K-III may con-
tribute to regulate its activity and speciﬁcity.
Although considerable efforts have been made to
understand how PtdIns3P is formed by PI3K-III, we
are also beginning to learn about the metabolism of
this lipid. Three known routes for PtdIns3P metabo-
lism have been described: degradation by lysosomal
lipases, phosphorylation by the PtdIns3P 5-kinase
Fab1⁄PIKfyve, and dephosphorylation by 3-phospha-
tases [94]. It is worth noting that Fab1⁄PIKfyve is
itself a PtdIns3P binding protein [95], and that
MTM1 and MTMR2, two phosphatases capable of
dephosphorylating PtdIns3P, can associate with PI3K-III
on endosomal membranes [96,97]. This suggests a tight
regulation of PtdIns3P formation and turnover, and it
will be interesting to determine whether PIKfyve and
MTM1⁄MTMR2 may play any role in tumourigenesis.
Even though it is assumed that PI3K-III functions as
tumour suppressor through its ability to produce
PtdIns3P at the correct intracellular membranes, this
has not been formally demonstrated and, to date, we do
not know whether the catalytic subunit of PI3K-III,
VPS34, is a tumour suppressor. Further studies should
clarify this, and it will also be important to establish
whether the catalytic function of VPS34 is required for
its eventual tumour suppressor function.
If we nevertheless accept that PI3K-III acts as
tumour suppressor through PtdIns3P generation, can
this be exploited in cancer diagnosis and therapy?
Because it is much easier to inhibit an enzyme phar-
macologically than to boost its function, the tumour
promotor PI3K-I is a more attractive drug target
than the tumour suppressor PI3K-III. On the other
hand, we know that PtdIns3P can be dephosphoryl-
ated and that PI3K-III undergoes negative regulation
[11,12], and alleviation of these inhibitory mechanisms
might provide a viable strategy towards increasing the
tumour suppressor activity of PI3K-III and its cata-
lytic product in cancer treatment. More straightfor-
wardly, knowing that PI3K-III subunits such as
Beclin 1 and UVRAG are frequently downregulated
or mutated in cancers [6,7,67,98,99], it will be interest-
ing to perform systematic analyses of PI3K-III subun-
its and key PtdIns3P effectors in various cancers.
Such studies should reveal mutational and expression-
based signatures that can be used to predict the
outcome of disease, and to guide the choice of thera-
peutic regimens.
Fig. 3. Alternative tumour suppressor
mechanisms of PI3K-III. Three alternative
(hypothetic) tumour suppressor mechanisms
downstream of PtdIns3P formation are
shown. The relative importance of these
mechanisms in the tumour suppressor
activity of PI3K-III subunits remains to be
established.
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